Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Rapid treatment of moderate to severe hypertension safe, feasible in routine practice

29 Oct 2019

A recent study has shown the feasibility and safety of implementing the accelerated management of treatment-naïve grade II/III hypertension in routine practice, with no evidence suggesting harm.

Fifty-four of the 55 participants included in the study completed the protocol. Of these, 69±12.3 percent achieved office target blood pressure (BP) at their final visit despite a high average starting BP of 175/103 mm Hg. This was driven by significant reductions in both their office and ambulatory BP. Fifty-one percent of participants at office target BP were above target on ambulatory measurement.

In adherence testing, 92 percent of participants were adherent to treatment at their final visit.

“Further large-scale randomized studies of rapid, adaptive treatment, including a cost-effectiveness analysis, are required,” the investigators said.

This single-centre, before and after interventional study examined newly diagnosed, never-treated, grade II/III hypertensive patients with a daytime average systolic ambulatory BP ≥150 mm Hg to target within 18 weeks. The proportion at office target BP at 18 weeks was determined, along with office and ambulatory BP change from baseline to after the intervention.

The investigators designed the protocol to maximize medication adherence, including a low threshold for treatment adaptation. They also assessed safety through close monitoring of adverse events and protocol discontinuation.

“Rapid treatment to target in hypertension may have beneficial effects on long-term outcomes,” the investigators said. “This has led to a new recommendation in the 2018 European hypertension guidelines for patients with grade II/III hypertension to be treated to target within 3 months.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.